As we have previously reported, Boehringer Ingelheim, the manufacturer of Pradaxa, has been sanctioned during the course of the federal litigation for destroying relevant documents. In a recent Case Management Order, Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, revisited the manufacturer’s misconduct and fixed new sanctions.

In the recent Order, Judge Herndon found “the wrongs here are egregious” and observed that plaintiffs’ ability to pursue their case may have been greatly and unfairly harmed by Boehringer’s actions. Judge Herndon wrote, “the Court’s imposition of a fine is a measured action, designed to let the defendants know that the Court’s Order and the Court deserve respect.” Judge Herndon affirmed the fine of $931,500.00 that he had previously imposed. Additionally, the latest order requires Boehringer to pay certain expenses incurred by plaintiffs’ attorneys as they take depositions of individuals employed by the drug maker located in Europe. Judge Herndon is requiring Boehringer to pay plaintiffs’ counsel for necessary office space in Amsterdam as well as for the costs of traveling, videographers, interpreters and court reporters retroactively, from December 9, 2013 through August 2014.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Judge David R. Herndon, Chief Judge of United States District Court, presiding over the litigation, recently entered scheduling orders for the first two bellwether trials. The first trial will begin on September 8, 2014, while the second trial is scheduled to begin on December 1, 2014.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

As we have previously reported, Judge David R. Herndon, Chief Judge of United States District Court, presiding over the litigation, recently sanctioned the manufacturer of Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc., over $931,000 for failing to preserve documents. Plaintiffs’ attorneys were concerned that the German-based drug maker continued to improperly withhold other documents related to the drug. Judge Herndon agreed and on January 29, 2014, ordered Boehringer Ingelheim to unseal 85 documents which had previously been marked as confidential. Plaintiffs will continue to request information related to the safety and marketing of Pradaxa.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use.

Physicians and analysts have commented that the health risks associated with Pradaxa are significant. As Forbes reports, the FDA plans to address these lingering concerns. The FDA posted a request for public comment on a study it plans to conduct regarding the safety of Pradaxa. The study will “assess systematically the rates of bleeding and thromboembolic outcomes associated with the use of dabigatran and warfarin for patients with atrial fibrillation.” The major purpose of the study is to identify groups of patients who are at high risk for major bleeding events with Pradaxa.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

The use of Pradaxa has been linked to serious injury. There are nearly 2,000 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant. Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, recently decided that Boehringer Ingelheim, maker of Pradaxa, had acted “in bad faith” by failing to preserve documents related to the drug’s development and marketing. Judge Herndon reportedly found that Boehringer’s behavior was “egregious” and “grossly inadequate” and justified a sanction of more than $931,000. Plaintiffs’ attorneys argued that Boehringer marketed Pradaxa knowing it could cause bleed-out deaths. It is alleged that Pradaxa is linked to more than 500 bleeding-related deaths over a two year period. In addition to the monetary penalties, Judge Herndon ordered Boehringer executives to turn over files and respond to additional document requests.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court in the Southern District of Illinois. Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant.  Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Judge David R. Herndon, Chief Judge United States District Court, presiding over the litigation, recently signed Case Management Order 48. Judge Herndon ordered the parties to “designate up to three cases for inclusion as an early trial case” by December 16, 2013. The Court will select four cases for trial by January 23, 2014. The current trial dates for these cases are set for February 16, 2014; August 11, 2014; November 3, 2014 and January 5, 2015.

If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court.  The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes.  Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant.  Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

The maker of the drug, Boehringer Ingelheim, recently updated label warnings of Pradaxa to include the risk of a blood platelet disorder.   The label warns of an increased risk of thrombocytopenia, a drop in blood platelets that can cause internal bleeding.  Many of the current individuals involved in the Pradaxa litigation have experienced internal bleeding.  You can read the updated label warning here.

The devastating consequences of Pradaxa use will likely continue. If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 cases currently pending in federal court.  The lawsuits allege that Pradaxa, manufactured by Boehringer Ingelheim, Inc., has resulted in devastating and sometimes fatal outcomes.  Pradaxa is a blood thinner that was marketed to replace warfarin, a commonly used anticoagulant.  Unfortunately, there is no readily-available antidote for the internal bleeding that can sometimes occur in patients treated with Pradaxa.

Plaintiffs’ counsel in the Multi District Litigation (MDL) pending in Chicago, Illinois has successfully argued for the production of certain Boehringer Ingelheim’s employee personnel records.  The recent Court Order directs the company to disclose employee reviews and bonuses related to Pradaxa for company witnesses that played a role in the development, approval or marketing of the drug.

The devastating consequences of Pradaxa use will likely continue. If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

As we have previously reported, the use of Pradaxa has been linked to serious injury.  There are nearly 600 lawsuits pending in federal court.  The Multi District Litigation (MDL), centralized in a Chicago federal court, continues to move forward.  The next Status Conference in the Pradaxa litigation has been schedule for the middle of May.

Trials are currently scheduled for August 2014 through February 2015.  The court presiding over the Pradaxa litigation continues to take an active role in the prompt and efficient resolution of the cases.

The devastating consequences of Pradaxa use will likely continue. If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.

A study by the University of North Carolina found that Pradaxa may increase the risk of some viral infections, such as flu and myocarditis, and infection of the heart.  The study also affirms that the blood thinner blocks key components of the human blood clotting system.

Pradaxa works by inhibiting thrombin, the body’s central coagulation activator of the blood clotting system.  By blocking the thrombin activity, the drug disturbs the “protease cascade of molecular events that normally occurs during coagulation.”  The new study shows that, although clot formation is reduced, an unintended consequence may emerge. The study reported that “blocking thrombin reduces the innate immune response to viral infection.”  This research will be published in the March 2013 issue of the Journal of Clinical Investigation.

The devastating consequences of Pradaxa use will likely continue. If you or a loved one has experienced serious side effects after taking Pradaxa, you can contact Stark & Stark and speak to one of the Mass Tort attorneys, free of charge, who can help assess any claims that you might have against Boehringer Ingelheim Pharmaceuticals, Inc.